More on PRLD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (4.3 Score)
- Holders

Upcoming Events

- Earnings (5/6/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Prelude Therapeutics Inc. (NQ:PRLD)
Delayed: 3.23 +0.11 (3.53%)
Prev. Close $3.12  
Open$3.05 
52 Wk High$ 
52 Wk Low$ 
Day High$3.38 
Day Low$3.05 
P/E N/A  
EPS$ 
Volume249,313 

Friends, Peers and Foes (?): ONCY, INCY, IMNM, ALXO, ERAS (more...)

Feb 13, 2026 04:02 PM Form SCHEDULE 13G/A Prelude Therapeutics Filed by: Vaddi Krishna
Feb 5, 2026 04:14 PM Form 4 Prelude Therapeutics For: Feb 04 Filed by: Combs Andrew
Feb 5, 2026 04:13 PM Form 4 Prelude Therapeutics For: Feb 04 Filed by: Scherle Peggy
Feb 5, 2026 04:12 PM Form 4 Prelude Therapeutics For: Feb 04 Filed by: Lim Bryant David
Feb 5, 2026 04:11 PM Form 4 Prelude Therapeutics For: Feb 04 Filed by: Vaddi Krishna
Feb 5, 2026 09:26 AM The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Feb 4, 2026 04:50 AM Prelude Therapeutics (PRLD) Reiterated at Market Outperform by Citizens: 'Well-Capitalized'
Feb 3, 2026 09:11 AM Form 8-K Prelude Therapeutics For: Jan 29
Feb 3, 2026 09:00 AM Prelude Therapeutics gets FDA clearance for JAK2 inhibitor trial
Feb 3, 2026 09:00 AM Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
View All Articles

Entities mentioned with PRLD

View All Entities